Literature DB >> 28680133

Systemic sclerosis: Choosing patients wisely when treating interstitial lung disease.

Richard M Silver1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28680133     DOI： 10.1038/nrrheum.2017.103

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Cyclophosphamide versus placebo in scleroderma lung disease.

Authors:  Donald P Tashkin; Robert Elashoff; Philip J Clements; Jonathan Goldin; Michael D Roth; Daniel E Furst; Edgar Arriola; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

Review 2.  Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.

Authors:  Guillaume Lefèvre; Luc Dauchet; Eric Hachulla; David Montani; Vincent Sobanski; Marc Lambert; Pierre-Yves Hatron; Marc Humbert; David Launay
Journal:  Arthritis Rheum       Date:  2013-09

3.  Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.

Authors:  Nicole S Goh; Rachel K Hoyles; Christopher P Denton; David M Hansell; Elisabetta A Renzoni; Toby M Maher; Andrew G Nicholson; Athol U Wells
Journal:  Arthritis Rheumatol       Date:  2017-07-18       Impact factor: 10.995

4.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Authors:  Rachel K Hoyles; Ross W Ellis; Jessica Wellsbury; Belinda Lees; Pauline Newlands; Nicole S L Goh; Christopher Roberts; Sujal Desai; Ariane L Herrick; Neil J McHugh; Noeleen M Foley; Stanley B Pearson; Paul Emery; Douglas J Veale; Christopher P Denton; Athol U Wells; Carol M Black; Roland M du Bois
Journal:  Arthritis Rheum       Date:  2006-12

5.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

Authors:  Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

6.  Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.

Authors:  Michael D Roth; Chi-Hong Tseng; Philip J Clements; Daniel E Furst; Donald P Tashkin; Jonathan G Goldin; Dinesh Khanna; Eric C Kleerup; Ning Li; David Elashoff; Robert M Elashoff
Journal:  Arthritis Rheum       Date:  2011-09

7.  Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.

Authors:  R M Silver; J H Warrick; M B Kinsella; L S Staudt; M H Baumann; C Strange
Journal:  J Rheumatol       Date:  1993-05       Impact factor: 4.666

8.  Determinants of morbidity and mortality of systemic sclerosis in Canada.

Authors:  Firas F Al-Dhaher; Janet E Pope; Janine M Ouimet
Journal:  Semin Arthritis Rheum       Date:  2008-08-15       Impact factor: 5.532

9.  Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials.

Authors:  Dinesh Khanna; Vivek Nagaraja; Chi-Hong Tseng; Fereidoun Abtin; Robert Suh; Grace Kim; Athol Wells; Daniel E Furst; Philip J Clements; Michael D Roth; Donald P Tashkin; Jonathan Goldin
Journal:  Arthritis Res Ther       Date:  2015-12-23       Impact factor: 5.156

10.  Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Authors:  Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff
Journal:  Lancet Respir Med       Date:  2016-07-25       Impact factor: 30.700
  10 in total
  1 in total

1.  Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.

Authors:  David Roofeh; Celia J F Lin; Jonathan Goldin; Grace Hyun Kim; Daniel E Furst; Christopher P Denton; Suiyuan Huang; Dinesh Khanna
Journal:  Arthritis Rheumatol       Date:  2021-05-25       Impact factor: 15.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.